trending Market Intelligence /marketintelligence/en/news-insights/trending/Q0aN9VW4jBAo6BM3IT6XTw2 content esgSubNav
In This List

Eleven Biotherapeutics CFO resigns; interim replacement named

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook

Blog

The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism


Eleven Biotherapeutics CFO resigns; interim replacement named

John McCabe resigned as CFO of Eleven Biotherapeutics Inc., effective Oct. 20.

McCabe did not resign due to any disagreements relating to the company's operations, policies or practices or any other company officer or director.

Eleven Biotherapeutics appointed Richard Fitzgerald as interim CFO, effective Oct. 13.

Fitzgerald most recently served as a consultant to private life science based companies from July through October. Previously, Fitzgerald served as CFO of medical device maker PAVmed Inc. from October 2015 through March 2017.